Marksans Pharma Limited operates in the Pharmaceutical preparations sector. Marksans Pharma Limited (Marksans) is a holding company. The Company is primarily engaged in the business of manufacturing and marketing of pharmaceutical formulations. It is also engaged in research and development (R&D) and offering contract research and manufacturing services (CRAMS) to global pharmaceutical companies. The R&D capabilities include dossier development service, chemical synthesis and process optimization, formulation development and specified drug delivery system. Its domestic formulation business includes Criticare division, Cerebella division, and Zenmark and Mark Remedies divisions. Criticare division is engaged in oncology and critical care therapy. Its brands are MARKPARIN and EPIGROF. Cerebella division is the specialty division marketing drugs meant for lifestyle diseases, neuro-psychiatrist and psychiatric therapy. Its brands include BAZZY, CITOFAST, GABELLA M, XENOTRIL. On July 28, 2010, it disposed its active pharmaceuticals ingredients (API) division. In our complete report available for purchase the company is compared to: Arvind Remedies Limited, Neuland Laboratories Limited and Venus Remedies Ltd.